Denmark · Delayed Price · Currency is DKK ViroGates Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 8% to DKK 5.3 million, with net loss improving by 28% and a strengthened cash position. Regulatory clarity was achieved for U.S. market entry, and product development for the longevity segment advanced, with key launches expected in 2026–2027.
-
Q3 revenue rose 49% year-over-year, with operating loss reduced by 21% and net loss down 20%. Focus is shifting to the longevity market, supported by new distributor partnerships and ongoing regulatory efforts for FDA and EMA clearances.
-
Revenue remained flat at DKK 1.2 million in Q1 2025, but net loss narrowed by 23% due to cost reductions. The company expanded its Sobi partnership for regulatory work and increased recurring customers, focusing on the longevity segment for future growth.
Fiscal Year 2024
-
Revenue fell 12% and net loss widened to DKK 14.4 million, driven by lower hospital and research sales. Strategic shift to longevity and US market entry underway, supported by new partnerships and a capital raise.
-
Revenue fell 29% year-over-year to DKK 3.396 million, with a strategic shift toward longevity diagnostics and a new U.S. distribution agreement. Operating loss increased, but cash position remains stable, and the company is advancing FDA approval efforts with Sobi.
-
Revenue for H1 2024 fell 11% year-over-year due to slow hospital sales, but growth in the longevity segment and stable ELISA sales provided some offset. Operating loss increased, and management is focusing on short-term revenue from new markets while maintaining cost discipline.